Novigenix SA’s Post

Transforming Cancer Treatment with Precision Medicine Relapsed and refractory cancers pose significant challenges, but precision oncology is paving the way for better outcomes. By using advanced genomic profiling and functional precision medicine, targeted therapies are now more effective and less toxic. Discover the future of cancer care! #CancerResearch #PrecisionMedicine #Oncology

#podcast Sanjeev Redkar, Co-Founder, Executive Director, and President of Apollomics, focuses on difficult-to-treat cancers, such as lung cancer, brain cancer, and leukemias, not served by immune checkpoint inhibitors. Their approach targets the thematic pathway in cancer cells responsible for their growth and proliferation. In their drug development, AI and data analysis drive precision-targeted therapies based on tumor molecular profiling. Developing the drugs Vebreltinib and Uproleselan #RareDiseases #Cancer #LungCancer #Leukemias #BrainCancer #RareCancers #NextGenSequencing #MolecularProfiling #CancerMolecularProfiling #TumorMolecularProfiling Apollomics.com https://lnkd.in/gydpqDEs

Classification of Breast Cancer Using FNA Biopsies 🩺 For women facing breast cancer, proper classification is key to effective treatment. A Fine Needle Aspiration (FNA) biopsy can help provide an early diagnosis, leading to quicker treatment decisions. Breast cancer classification includes: Histopathology: Identifies the origin of cancer cells. Grade: Compares cancer cells to normal cells—the higher the grade, the worse the prognosis. Stage: Determines if the cancer has spread, affecting survival rates. Receptor Status: Hormone sensitivity impacts treatment options. DNA: Genetic mutations guide personalized therapies. Early classification leads to better outcomes. #BreastCancerAwareness #FNA #Biopsy #BreastCancerClassification #HealthMatters

In this video we address pressing issues in breast cancer diagnostics. Featuring insights from clinical experts Prof Daniele Generali, Dr Dana Cohen, Professor John Bartlett, and Dr Dario de Biase. The discussion revolves around the challenges posed by inconsistencies in breast cancer diagnosis and the crucial need for reliable technology and tests to enhance patient outcomes. 🗣️ Dr Cohen highlights the dilemma faced by physicians and oncologists: "How can you report or treat a patient when you know that the technology at hand may provide an inaccurate answer?" Discover how MammaTyper® emerges as a solution, offering tools to discern between breast cancer subtypes and assess gene expression across a broad spectrum.  #CancerDiagnostics, #Pathology, #Oncology #HealthInnovation.

Biomarkers are emerging as the highest value proposition in cancer medicine today. Anna Barker and colleagues stress the need to see biomarkers as keys to biological systems, essential for tackling complex diseases like cancer. This shift opens up fresh perspectives for diagnosis and therapy. It's clear that big data and AI will play a critical role in advancing next-gen biomarker discovery, marking an inevitable leap forward in precision oncology. https://hubs.li/Q02q1Chr0 #spatialbiomarkers #ai #precisionmedicine #precisiononcology #digitalpathology

Hats off to the Singapore Gastric Cancer Consortium Duke-NUS Medical School for this compelling analysis: 1,256 gastric samples across 692 subjects from a prospective 10-year study provide a better understanding of gastric cancer progression👉https://bit.ly/3V6rEyK This #Fridayread published in Cancer Cell shows how GeoMx DSP was used to perform spatiotemporal genomic profiling and was key for revealing significant lineage heterogeneity. #spatialprofiling #gastriccancer #tissueheterogeneity

Remond Fijneman et al. developed a mutation-independent method to estimate tumor fraction using cfDNA fragmentation patterns called DELFI-TF. In 153 metastatic colorectal cancer patients (CAIRO5 trial), DELFI-TF predicted treatment response, progression-free survival, and overall survival better than imaging or CEA. Validation in a lung cancer cohort shows its potential for monitoring and outcome prediction. 💡 I wonder how batch effects impact DELFI-TF accuracy across different labs/cohorts and how we can minimize variability? #CancerResearch #cfDNA #ctDNA #fragmentomics #LiquidBiopsy

Classification of Breast Cancer Using FNA Biopsies 🩺 For women facing breast cancer, proper classification is key to effective treatment. A Fine Needle Aspiration (FNA) biopsy can help provide an early diagnosis, leading to quicker treatment decisions. Breast cancer classification includes: Histopathology: Identifies the origin of cancer cells. Grade: Compares cancer cells to normal cells—the higher the grade, the worse the prognosis. Stage: Determines if the cancer has spread, affecting survival rates. Receptor Status: Hormone sensitivity impacts treatment options. DNA: Genetic mutations guide personalized therapies. Early classification leads to better outcomes. #BreastCancerAwareness #FNA #Biopsy #BreastCancerClassification #HealthMatters

No more guesswork in cancer diagnosis with Targeted Bioscience! Our spatial profiling solutions provide early insights into the tumor microenvironment, revealing crucial details about tumor heterogeneity, immune response, and therapeutic targets. Ready to tap into proper precision for cancer diagnosis? Simply message us "Spatial profiling" to get started!

🌟 Unlock Insights into Cutting-Edge Cancer Research! 🌟 Join Agilent Technologies and The Pathologist for an on-demand webinar on how tumor genomic profiling is democratizing cancer research. Hear from Michael Ruvolo and Danielle Fletcher about how innovative solution are transforming personalized medicine research. Don’t miss this chance to deepen your understanding and stay ahead in the field of oncology research. Register now to access this insightful webinar! 👉 Register Here: https://bit.ly/3XjlLh1 #CancerResearch #GenomicProfiling #PersonalizedMedicine #Oncology #Webinar